business / news / / Bloomberg
Gilead will pay $3.15 billion upfront in cash, and up to $1.85 billion more if certain milestones are met.
Gilead Sciences will acquire Tubulis GmbH for up to $5 billion.
KEY POINTS
- The deal includes a $3.15 billion upfront cash payment and $1.85 billion in milestone payments.
- Tubulis specializes in a new area of cancer drug development.
- The acquisition is expected to close in the second quarter of this year.
COMPANIES
Summarized by Newsio from Bloomberg. How we summarize →